Results 221 to 230 of about 264,257 (370)

Review on enhancing clinical decision support system using machine learning

CAAI Transactions on Intelligence Technology, EarlyView.
Abstract Clinical decision‐making is a complex patient‐centred process. For an informed clinical decision, the input data is very thorough ranging from detailed family history, environmental history, social history, health‐risk assessments, and prior relevant medical cases.
Anum Masood, Usman Naseem, Junaid Rashid, Jungeun Kim, Imran Razzak   +4 more
wiley   +1 more source

Diffuse Large B-Cell Lymphoma Combined With Paroxysmal Nocturnal Hemoglobinuria: A Rare Case Report. [PDF]

Clin Case Rep
Liu ZZ, Di DL, Feng AH, Yu J, Wang HY, Qin L.   +5 more
europepmc   +1 more source

Meta‐Analysis: High anti‐HBs Titers are Associated with Significantly Reduced Risk of Hepatitis B Virus Reactivation During Rituximab Treatment

Alimentary Pharmacology &Therapeutics, EarlyView.
This meta‐analysis demonstrates a significantly lower risk for HBV reactivation on rituximab if anti‐HBs is > 100 iU/L (3.5%, CI: 1.8%–6.9%) vs. anti‐HBs between 10 and 100 iU/L (13.8%, CI: 8.8%–20.8%) and anti‐HBs negative (27.3%, CI: 20.0%–36.0%). Thus, if anti‐HBs titer is > 10 iU/L, monitoring could be considered.
Shiva Poola, MaryKate Kratzer, Kerry Sewell, Zikun Yang, Hans L. Tillmann   +4 more
wiley   +1 more source

Prognostic value of lymphocyte subsets in diffuse large B cell lymphoma. [PDF]

Front Oncol
Qiu L, Xing L, Zhao M, Sun B, Zhou X, Li M, Ying G, Zhang H, Tian C.   +8 more
europepmc   +1 more source

BGB-3111-218: Single-arm, open-label, multicenter study of the Bruton tyrosine kinase (BTK) inhibitor zanubrutinib (zanu) in patients with CD79B-mutated Relapsed/Refractory (R/R) diffuse large B-cell lymphoma (DLBCL) [PDF]

Ou Bai, Wenjuan Yu, Wenbin Qian, Weili Zhao   +3 more
openalex   +1 more source

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

British Journal of Haematology, EarlyView.
The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.
Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, Merve Apaydın Kayer, Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Deniz Gören, Tayfur Toptaş, Turgay Ulaş, Özgür Mehtap, Mehmet Sinan Dal, Olga Meltem Akay, Muhlis Cem Ar, Güray Saydam, Fevzi Altuntaş, Elif Birtaş Ateşoğlu, Burhan Ferhanoğlu   +24 more
wiley   +1 more source

SEOM-GOTEL clinical guidelines on diffuse large B-cell lymphoma (update 2025). [PDF]

Clin Transl Oncol
Gumà J, Palazón-Carrión N, Rueda-Domínguez A, Sequero S, Calvo V, García-Arroyo R, Gómez-Codina J, Llanos M, Martínez-Banaclocha N, Provencio M.   +9 more
europepmc   +1 more source

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Nature Medicine, 2015
W. Wilson, R. Young, R. Schmitz, Yandan Yang, S. Pittaluga, George W. Wright, C. Lih, P. Williams, A. Shaffer, J. Gerecitano, J. Gerecitano, S. Vos, A. Goy, V. Kenkre, P. Barr, K. Blum, A. Shustov, R. Advani, N. Fowler, J. Vose, R. Elstrom, T. Habermann, J. Barrientos, J. Mcgreivy, M. Fardis, B. Chang, F. Clow, B. Munneke, D. Moussa, D. Beaupre, L. Staudt   +30 more
semanticscholar   +1 more source

NEAT1 lncRNA overexpression results in short‐term progression and poor treatment outcome in childhood B‐ALL

British Journal of Haematology, EarlyView.
Childhood acute lymphoblastic leukaemia (chALL) remains the most prevalent malignancy in children and adolescents. Improving risk stratification and providing personalized prognosis and treatment remain major clinical challenges. NEAT1 lncRNA overexpression constitutes a powerful, independent predictor of poor treatment outcomes and disease progression
Marieta Xagorari, Antonios Marmarinos, Dimitrios Doganis, Maria Nikita, Evgenia Magkou, Angeliki‐Eleni Sfetsiori, Margarita Baka, Lydia Kossiva, Sofia Pasparaki, Alexandra Soldatou, Maria Tsolia, Andreas Scorilas, Dimitrios Gourgiotis, Margaritis Avgeris   +13 more
wiley   +1 more source

Cathepsins effect on diffuse large B cell lymphoma risk: A Mendelian randomization study. [PDF]

Medicine (Baltimore)
Lu C, Chen Q, Shi Y, Deng Y, Wang C, Yu L.   +5 more
europepmc   +1 more source